Comparison of hyperkalemic risk in hospitalized patients treated with different angiotensin receptor blockers: A retrospective cohort study using a Korean clinical research database

American Journal of Cardiovascular Drugs

Volumn 12, Issue 4, 2012, Pages 255-262

  Park, Inwhee ^a   Sheen, Seung Soo ^a   Lim, Hong Seok ^a   Yoon, Dukyong ^a   Park, Man Young ^a   Lee, Suk Hyang ^b   Shin, Gyu Tae ^a   Kim, Heungsoo ^a   Park, Rae Woong ^a  

^a Ajou University School of Medicine   (South Korea)

^b Ajou University   (South Korea)

Author keywords

angiotensin receptor antagonists; hyperkalaemia; telmisartan

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPROSARTAN; IRBESARTAN; LOSARTAN; NONSTEROID ANTIINFLAMMATORY AGENT; OLMESARTAN; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; TELMISARTAN; VALSARTAN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; FATALITY; FEMALE; GLOMERULUS FILTRATION; HEART FAILURE; HOSPITAL PATIENT; HUMAN; HYPERKALEMIA; INCIDENCE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT;

ADULT; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; BIOMEDICAL RESEARCH; COHORT STUDIES; DATABASES, FACTUAL; DATABASES, PHARMACEUTICAL; FEMALE; HOSPITALIZATION; HUMANS; HYPERKALEMIA; KOREA; MALE; MIDDLE AGED; PPAR GAMMA; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK;

EID: 84863939917     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11634470-000000000-00000     Document Type: Article

References (24)

1. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 Mar 23; 359 (9311): 995-1003
2. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001 Sep 20; 345 (12): 851-60
3. Schrader J, Luders S, Kulschewski A, et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005 Jun; 36 (6): 1218-26
4. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000 Feb 19; 355 (9204): 637-45
5. Thompson CA. New angiotensin-receptor blocker approved by FDA. Am J Health Syst Pharm 2011 Apr 1; 68 (7): 550
6. Shier DN, Kusano E, Stoner GD, et al. Production of renin, angiotensin II, and aldosterone by adrenal explant cultures: response to potassium and converting enzyme inhibition. Endocrinology 1989 Jul; 125 (1): 486-91
7. GrangerCB, ErtlG,Kuch J, et al.Randomized trial of candesartan cilexetil in the treatment of patientswith congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors.AmHeart J 2000Apr; 139 (4): 609-17
8. Sadjadi SA, McMillan JI, Jaipaul N, et al. A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers. Ther Clin Risk Manag 2009 Jun; 5 (3): 547-52
9. Winkelmayer WC, Zhang Z, Shahinfar S, et al. Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes. Diabetes Care 2006 Oct; 29 (10): 2210-7
10. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008 Apr 10; 358 (15): 1547-59
11. Bootsma JE, Warle-van Herwaarden MF, Verbeek AL, et al. Adherence to biochemical monitoring recommendations in patients starting with Renin Angiotensin system inhibitors: a retrospective cohort study in the Netherlands. Drug Saf 2011 Jul 1; 34 (7): 605-14
12. Schaefer TJ, Wolford RW. Disorders of potassium. Emerg Med Clin NorthAm 2005 Aug; 23 (3): 723-47, viii-ix
13. Park MY, Yoon D, Lee K, et al. A novel algorithm for detection of adverse drug reaction signals using a hospital electronic medical record database. Pharmacoepidemiol Drug Saf 2011 Jun; 20 (6): 598-607
14. Yoon D, Park M, Choi N, et al.Detection ofAdverse drug reaction signals using an electronic health records database: Comparison of the Laboratory Extreme Abnormality Ratio (CLEAR). Clin Pharmacol Ther 2012 Mar; 91 (3): 467-74
15. Shlipak MG. Pharmacotherapy for heart failure in patients with renal insufficiency. nn Intern Med 2003 Jun 3; 138 (11): 917-24
16. Sundararajan V, Henderson T, Perry C, et al. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol 2004 Dec; 57 (12): 1288-94
17. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999 Mar 16; 130 (6): 461-70
18. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. NEngl J Med 2001 Dec 6; 345 (23): 1667-75
19. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003 Nov 13; 349 (20): 1893-906
20. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensinaldosterone system. N Engl J Med 2004 Aug 5; 351 (6): 585-92
21. Schupp M, Janke J, Clasen R, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004 May 4; 109 (17): 2054-7
22. Sanchez RA, Masnatta LD, Pesiney C, et al. Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives. J Hypertens 2008 Dec; 26 (12): 2393-8
23. Schmidt B, Schieffer B. Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites. J Med Chem 2003 Jun 5; 46 (12): 2261-70
24. Evans KJ, Greenberg A. Hyperkalemia: a review. J Intensive Care Med 2005 Sep-Oct; 20 (5): 272-90